TABLE 1.
Novel Interventions to Reduce Cardiovascular Risk
| Comorbidity | Target | Medications |
|---|---|---|
| Dyslipidemia | LDL-C Triglycerides Lipoprotein(a) | Monoclonal antibodies (alirocumab, evolocumab) siRNA (inclisiran) Icosapent ethyl ApoCIII-Lrx IONIS-APO(a)Rx |
| Inflammation | IL-1β | Canakinumab |
| Diabetes | SGLT-2 GLP-1 receptor | Canagliflozin, dapagliflozin, empaglifolozin Albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide, semaglutide |
| Obesity | Appetite Stomach capacity | Orlistat, locaserin, naltrexone-buproprion, phentermine-topiramate, liraglutide Gastric bypass, sleeve gastrectomy, adjustable gastric band, biliopancreatic diversion with duodenal switch |
| Hypertension | Vasopeptidase, Aldosterone synthase, Soluble epoxide hydrolase, natriuretic peptide A, vasoactive intestinal peptide receptor 2 Vaccines Catheter-based interventions | Vaccines against angiotensin II and its receptor type I Renal denervation Baroreflex activation therapy |
| Antithrombotic therapy | Factor Xa | Rivaroxaban |